Trials / Completed
CompletedNCT01982552
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 147 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for treatment of plaque psoriasis under real-life conditions.
Conditions
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-11-13
- Last updated
- 2018-02-05
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01982552. Inclusion in this directory is not an endorsement.